HR-Positive Breast Cancer Content | Docwire News

HR-Positive Breast Cancer

Advertisement

PENELOPE-B Final Analysis: Palbociclib Shows No Survival Benefit in High-Risk HR+/HER2- Breast Cancer

Brandon TwyfordHR Breast Cancer | April 5, 2025

Final results from the PENELOPE-B trial show palbociclib did not improve survival in high-risk HR+/HER2– breast cancer.

Interim SERENA-6 Data: Camizestrant Significantly Improves PFS in First-Line HR+/HER2- Advanced Breast Cancer With ESR1 Mutations

Yvette C. TerrieHR Breast Cancer | April 4, 2025

Camizestrant plus CDK4/6 inhibition significantly improved PFS in HR+/HER2– advanced breast cancer with ESR1 mutations.

Dr. Mik Rinne on the First Promising CDK2 Inhibitor in Combination to Treat HR+/HER2- Breast Cancer

Dr. Mik RinneHR Breast Cancer | July 19, 2024

Dr. Mik Rinne discusses a study on the efficacy of the CDK2 inhibitor BLU-222 in patients with HR+/HER2- breast cancer.

Advertisement

Advertisement

Advertisement

Latest News

Study Shows That Black Patients With Metastatic Breast Cancer Tend to Experience Higher Mortality Rates Than White Patients

April 6, 2025

PENELOPE-B Final Analysis: Palbociclib Shows No Survival Benefit in High-Risk HR+/HER2- Breast Cancer

April 5, 2025

EU Approves Enhertu for HR-Positive, HER2-Low, HER2-Ultralow Metastatic Breast Cancer Following Endocrine Therapy

April 4, 2025